Stock EXAS EXACT SCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Exact Sciences Corporation

Equities

EXAS

US30063P1057

Delayed Nasdaq
Other stock markets
 03:56:26 2024-05-29 pm EDT 		5-day change 1st Jan Change
44.89 USD -4.53% Intraday chart for Exact Sciences Corporation -16.12% -39.35%
May. 24 Sector Update: Health Care Stocks Advance Pre-Bell Friday MT
May. 24 Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ASCO®: Exact Sciences bekräftigt mit mehreren Datenpräsentationen seine langfristige Vorreiterrolle in der Krebsfrüherkennung und bei der Verbesserung von Behandlungsergebnissen
Sector Update: Health Care Stocks Advance Pre-Bell Friday
Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®
U.S. FDA advisers back approval for Guardant's cancer test
Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed
USA-Les valeurs à suivre à Wall Street (actualisé)
Exact Sciences Q1 Net Loss Widens, Revenue Increases; 2024 Revenue Outlook Maintained -- Shares Fall After Hours
Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024
Exact Sciences Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
Exact Sciences Corporation Announces Board Resignations
Exact Sciences Corporation Announces Executive Changes
Exact Sciences Signs Debt Exchange Deal, Placement of Convertible Notes
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
Exact Sciences Insider Sold Shares Worth $287,500, According to a Recent SEC Filing
Exact Sciences Insider Sold Shares Worth $356,302, According to a Recent SEC Filing
Exact Sciences Insider Sold Shares Worth $305,963, According to a Recent SEC Filing
Exact Sciences Corporation Provides Earnings Guidance for the first quarter and Year 2024
Exact Sciences' Q4 Loss Narrows, Revenue Increases; Sets 2024 Revenue Forecast
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EXAS Stock
  4. News Exact Sciences Corporation
  5. Other languages